Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

Novartis Pharmaceuticals clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1758
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Novartis Pharmaceuticals
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Novartis Pharmaceuticals. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 145–156 of 1,758 matching trials for sponsor Novartis Pharmaceuticals.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
rapcabtagene autoleucel
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
17
States / cities
Birmingham, Alabama • San Bernardino, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions
Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
13
States / cities
Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Completed Phase 3 Interventional

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

NCT04023552
View directory record Official record
Conditions
Cardiovascular Disease and Lipoprotein(a)
Interventions
TQJ230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
8,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
287
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Recruiting Phase 1 Interventional

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

NCT07660055
View directory record Official record
Conditions
Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
Interventions
[68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155
Diagnostic Test · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

NCT06726148
View directory record Official record
Conditions
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
Interventions
ECI830, ribociclib, fulvestrant
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Active, not recruiting Phase 4 Interventional

Pediatric Long-Term Follow-up and Rollover Study

NCT03975829
View directory record Official record
Conditions
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
Interventions
dabrafenib, trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 99 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191
View directory record Official record
Conditions
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Interventions
Asciminib, Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
9
States / cities
Denver, Colorado • Peoria, Illinois • Saint Paul, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib oral treatment, Ocrelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
44
States / cities
Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 100 Years
Enrollment
17,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
271
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 214 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Recruiting No phase listed Observational

A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice

NCT07779460
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
7,466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Ianalumab, Eltrombopag, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 1:08 PM EDT
Active, not recruiting Phase 3 Interventional

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

NCT02962414
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 1:08 PM EDT

About this Novartis Pharmaceuticals sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Novartis Pharmaceuticals is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Novartis Pharmaceuticals trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Novartis Pharmaceuticals.